Literature DB >> 26472403

TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.

Shih-Yao Lin1, Shu-Lang Liao2, Jin-Bon Hong3, Chia-Yu Chu3, Yi-Shuan Sheen3, Jie-Yang Jhuang1, Jia-Huei Tsai4, Jau-Yu Liau4.   

Abstract

BACKGROUND/AIMS: Ultraviolet light-signature mutations in the telomerase reverse transcriptase (TERT) gene promoter have been identified in cutaneous melanomas, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs). Whether these mutations also occur in periocular tumours, including periocular sebaceous carcinomas (PSCs) and in situ tumours, has not been studied.
METHODS: DNA extraction, PCR and Sanger sequencing were used to determine the frequency of TERT promoter mutations in periocular tumours. The presence of mutations was correlated with histological evidence of solar elastosis.
RESULTS: Sixty-three tumours were analysed. TERT promoter mutations were identified in 18 of 22 BCCs (82%), 6 of 10 SCCs (60%), 1 of 2 in situ SCCs (50%), 4 of 9 grade III conjunctival intraepithelial neoplasia (CIN III) (44%) and 0 of 20 PSCs (0%). For BCCs, TERT promoter mutations were not associated with the histological risk categories of the tumours. For CIN III cases, all of the three lesions with solar elastosis had TERT promoter mutations, whereas the mutation was found in only one of the six CIN III cases without solar elastosis.
CONCLUSIONS: We demonstrate that ultraviolet light-signature TERT promoter mutations are very common in periocular BCCs, SCCs and CIN III lesions, indicating important roles of ultraviolet light in the pathogenesis of these tumours. In addition, the mutations are present in in situ stage. By contrast, no TERT promoter mutation is found in PSCs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Conjunctiva; Eye Lids; Neoplasia; Pathology

Mesh:

Substances:

Year:  2015        PMID: 26472403     DOI: 10.1136/bjophthalmol-2015-307503

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Immunohistochemical and mutational status of telomerase reverse transcriptase in conjunctival squamous cell carcinoma.

Authors:  Perumal Jayaraj; Seema Sen; Kartikey Saxena; Jassika Gupta; Pranjal Vats; Seema Kashyap; Sheetal Chauhan; Neelam Pushker
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

Review 2.  Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.

Authors:  Tiantian Liu; Xiaotian Yuan; Dawei Xu
Journal:  Genes (Basel)       Date:  2016-07-18       Impact factor: 4.096

3.  Overexpression of miR-651-5p inhibits ultraviolet radiation-induced malignant biological behaviors of sebaceous gland carcinoma cells by targeting ZEB2.

Authors:  Haiyan Zhao; Xiaochun Yang; Juan Liu; Fang Han; Zhengrong Yang; Zhongyin Hu; Mingzhi Liu; Yan Mei
Journal:  Ann Transl Med       Date:  2022-05

Review 4.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

Review 5.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.